 |
88 Diseases |  |
13 Trials |
|
13 Trials |  |
791 News |  |
| «123456789101112» |
- |||| Vafseo (vadadustat) / Akebia Therap
Enrollment open: Study to Evaluate Vadadustat for Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Who Are Hyporesponsive to Erythropoiesis Stimulating Agents (clinicaltrials.gov) - May 30, 2017
P2, N=78, Recruiting, Sponsor: Akebia Therapeutics
Not yet recruiting --> Recruiting
- | Epogen (epoetin alfa) / Amgen
Enrollment change, Trial withdrawal, Trial primary completion date: Atorvastatin Reduces Chronic Inflammation and aVerage Epogen Dose (ARChIVED) (clinicaltrials.gov) - May 18, 2017
P=N/A, N=0, Withdrawn, Sponsor: Albert Einstein Healthcare Network
Not yet recruiting --> Recruiting N=35 --> 0 | Not yet recruiting --> Withdrawn | Trial primary completion date: Jan 2018 --> Mar 2017
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Metastases: DREXNECK: Induction Chemotherapy Followed by Cetuximab and Radiation Therapy for Head and Neck Cancer (clinicaltrials.gov) - May 9, 2017
P2, N=1, Completed, Sponsor: Drexel University College of Medicine
N=35 --> 0 | Not yet recruiting --> Withdrawn | Trial primary completion date: Jan 2018 --> Mar 2017 N=25 --> 1
- ||||| Evrenzo (roxadustat) / Astellas, AstraZeneca, FibroGen
Enrollment change, Trial primary completion date: Himalayas: Safety and Efficacy Study of Roxadustat (FG-4592) for the Treatment of Anemia in End-Stage Renal Disease (ESRD) Newly Initiated Dialysis Participants (clinicaltrials.gov) - May 8, 2017
P3, N=900, Recruiting, Sponsor: FibroGen
N=25 --> 1 N=750 --> 900 | Trial primary completion date: Jun 2017 --> Mar 2018
- ||||| Vafseo (vadadustat) / Akebia Therap
New P2 trial: Study to Evaluate Vadadustat for Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Who Are Hyporesponsive to Erythropoiesis Stimulating Agents (clinicaltrials.gov) - May 4, 2017
P2, N=78, Not yet recruiting, Sponsor: Akebia Therapeutics
- | Epogen (epoetin alfa) / Amgen
Combination therapy: NCI-2009-01173: Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia (clinicaltrials.gov) - Apr 26, 2017
P3, N=252, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=750 --> 900 | Trial primary completion date: Jun 2017 --> Mar 2018 Trial primary completion date: Apr 2017 --> Sep 2017
- | Epogen (epoetin alfa) / Amgen
Trial completion: Chemotherapy and Radiation Therapy With or Without Epoetin Alfa in Treating Patients With Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer (clinicaltrials.gov) - Apr 18, 2017
P3, N=1, Completed, Sponsor: Wake Forest University Health Sciences
Trial primary completion date: Apr 2017 --> Sep 2017 No longer recruiting --> Completed
- | Epogen (epoetin alfa) / Amgen
New P3 trial, Adverse events: PAEAN - Erythropoietin for Hypoxic Ischaemic Encephalopathy in Newborns (clinicaltrials.gov) - Mar 13, 2017
P3, N=300, Recruiting, Sponsor: University of Sydney
- ||||| Evrenzo (roxadustat) / FibroGen
Enrollment change, Trial primary completion date: Study to Evaluate the Efficacy and Safety of Roxadustat in the Treatment of Anemia in Participants With ESRD on Stable Dialysis (clinicaltrials.gov) - Feb 28, 2017
P3, N=820, Recruiting, Sponsor: FibroGen
No longer recruiting --> Completed N=600 --> 820 | Trial primary completion date: Jun 2017 --> Mar 2018
- ||||| Evrenzo (roxadustat) / Astellas, AstraZeneca, FibroGen
Enrollment change, Trial primary completion date: Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease, on Dialysis. (clinicaltrials.gov) - Feb 24, 2017
P3, N=2100, Recruiting, Sponsor: AstraZeneca
N=600 --> 820 | Trial primary completion date: Jun 2017 --> Mar 2018 N=1425 --> 2100 | Trial primary completion date: Feb 2017 --> Mar 2018
- | Epogen (epoetin alfa) / Amgen
New trial: Long Term Effects of Erythropoietin in Patients With Moderate to Severe Traumatic Brain Injury (clinicaltrials.gov) - Feb 23, 2017
P=N/A, N=603, Not yet recruiting, Sponsor: Australian and New Zealand Intensive Care Research Centre
- Epogen (epoetin alfa) / Amgen
Enrollment closed: Generation of Positive Biological Samples to Epoetin for Doping Control. (clinicaltrials.gov) - Feb 10, 2017
P1, N=2, Active, not recruiting, Sponsor: Parc de Salut Mar
N=1425 --> 2100 | Trial primary completion date: Feb 2017 --> Mar 2018 Not yet recruiting --> Active, not recruiting
- Epogen (epoetin alfa) / Amgen
Enrollment open, Trial initiation date, Trial primary completion date: Erythropoietin to Prevent Unnecessary Transfusions In Patients With Cyanotic CHD - A Prospective Control Trial (clinicaltrials.gov) - Feb 6, 2017
P2, N=40, Recruiting, Sponsor: University of California, San Diego
Not yet recruiting --> Active, not recruiting Not yet recruiting --> Recruiting | Initiation date: Sep 2016 --> Feb 2017 | Trial primary completion date: Sep 2018 --> Feb 2019
- ||||| Jesduvroq (daprodustat) / GSK, Kyowa Kirin
New P2a trial: Anemia Study in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-Blood Pressure (ASCEND-BP) (clinicaltrials.gov) - Jan 24, 2017
P2a, N=62, Not yet recruiting, Sponsor: GlaxoSmithKline
- |||| Musredo (molidustat) / Bayer
Trial completion: DIALOGUE5: Long Term Extension Study for the Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934 (clinicaltrials.gov) - Jan 11, 2017
P2, N=88, Completed, Sponsor: Bayer
Not yet recruiting --> Recruiting | Initiation date: Sep 2016 --> Feb 2017 | Trial primary completion date: Sep 2018 --> Feb 2019 Active, not recruiting --> Completed
- | Epogen (epoetin alfa) / Amgen
Enrollment open: High-dose Erythropoietin for Asphyxia and Encephalopathy (clinicaltrials.gov) - Jan 10, 2017
P3, N=500, Recruiting, Sponsor: University of California, San Francisco
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- | Epogen (epoetin alfa) / Amgen
Trial completion: Radiation Therapy With or Without Epoetin Alfa in Treating Anemic Patients With Head and Neck Cancer (clinicaltrials.gov) - Jan 3, 2017
P3, N=0, Completed, Sponsor: Radiation Therapy Oncology Group
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | Epogen (epoetin alfa) / Amgen
Trial initiation date, Trial primary completion date: High-dose Erythropoietin for Asphyxia and Encephalopathy (clinicaltrials.gov) - Dec 28, 2016
P3, N=500, Not yet recruiting, Sponsor: University of California, San Francisco
Active, not recruiting --> Completed Initiation date: Sep 2016 --> Jan 2017 | Trial primary completion date: Jan 2022 --> Jun 2022
- || Musredo (molidustat) / Bayer
Trial primary completion date: DIALOGUE5: Long Term Extension Study for the Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934 (clinicaltrials.gov) - Nov 3, 2016
P2, N=88, Active, not recruiting, Sponsor: Bayer
Initiation date: Sep 2016 --> Jan 2017 | Trial primary completion date: Jan 2022 --> Jun 2022 Trial primary completion date: Oct 2018 --> Nov 2016
- || Mircera (methoxy polyethylene glycol-epoetin beta) / Roche, CSL Behring
Trial primary completion date: A Study to Assess All-Cause Mortality and Cardiovascular Morbidity in Participants With Chronic Kidney Disease (CKD) on Dialysis and Those Not on Renal Replacement Therapy Receiving Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) or Reference Erythropoietin Stimulating Agents (ESAs) (clinicaltrials.gov) - Nov 3, 2016
P4, N=2828, Active, not recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Oct 2018 --> Nov 2016 Trial primary completion date: Nov 2019 --> Jul 2017
- ||||||| Mircera (methoxy polyethylene glycol-epoetin beta) / Roche, CSL Behring
Trial completion: A Study of Intravenous or Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients (clinicaltrials.gov) - Nov 1, 2016
P3, N=336, Completed, Sponsor: Hoffmann-La Roche
Trial primary completion date: Nov 2019 --> Jul 2017 No longer recruiting --> Completed
- Epogen (epoetin alfa) / Amgen
New P1 trial: Generation of Positive Biological Samples to Epoetin for Doping Control. (clinicaltrials.gov) - Sep 29, 2016
P1, N=5, Not yet recruiting, Sponsor: Parc de Salut Mar
- Epogen (epoetin alfa) / Amgen
Enrollment change: A Phase 2 Study to Evaluate the Safety and Effectiveness of Once Weekly or Once Every Two Week Dosing of Epoetin Alfa in Anemic Patients With Low- or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) (clinicaltrials.gov) - Sep 20, 2016
P2, N=0, Withdrawn, Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
No longer recruiting --> Completed N=100 --> 0
- Epogen (epoetin alfa) / Amgen
Enrollment change: Open-Label Extension Safety Study of PROCRIT in Patients With Anemia of Chronic Disease Due to Rheumatoid Arthritis (clinicaltrials.gov) - Sep 20, 2016
P2, N=0, Withdrawn, Sponsor: Ortho Biotech Products, L.P.
N=100 --> 0 N=200 --> 0
- || Epogen (epoetin alfa) / Amgen, Omontys (peginesatide) / Affymax
Phase classification: DIAMOND: Conversion Study From Epoetin Alfa to Monthly Peginesatide Injection in Patients With Chronic Kidney Disease on Dialysis (clinicaltrials.gov) - Sep 20, 2016
P3b, N=184, Completed, Sponsor: Takeda
N=200 --> 0 Phase classification: P3 --> P3b
- ||||| Evrenzo (roxadustat) / Astellas, AstraZeneca, FibroGen
Enrollment closed: FG-4592 for Treatment of Anemia in Subjects With Chronic Kidney Disease (clinicaltrials.gov) - Jul 29, 2016
P3, N=305, Active, not recruiting, Sponsor: FibroGen
Phase classification: P3 --> P3b Recruiting --> Active, not recruiting
- ||||| Evrenzo (roxadustat) / FibroGen
Enrollment closed, Trial primary completion date: Roxadustat in the Treatment of Anemia in End Stage Renal Disease (ESRD) Patients on Stable Dialysis (clinicaltrials.gov) - Jul 20, 2016
P3, N=838, Active, not recruiting, Sponsor: Astellas Pharma Europe B.V.
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2017 --> Jun 2017
- | Epogen (epoetin alfa) / Amgen
Trial completion, Enrollment change, Trial primary completion date, HEOR: CEDOSE: The Clinical Evaluation of the Dose of Erythropoietins Trial (clinicaltrials.gov) - Jul 19, 2016
P3, N=656, Completed, Sponsor: Giovanni FM Strippoli, MD
Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2017 --> Jun 2017 Recruiting --> Completed | N=900 --> 656 | Trial primary completion date: Dec 2013 --> Jul 2014
- | Epogen (epoetin alfa) / Amgen
Trial completion: Epoetin Alfa in Treating Anemia in Patients With Solid Tumors (clinicaltrials.gov) - Jul 16, 2016
P3, N=365, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Recruiting --> Completed | N=900 --> 656 | Trial primary completion date: Dec 2013 --> Jul 2014 Active, not recruiting --> Completed
- | Epogen (epoetin alfa) / Amgen
Trial completion: Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy (clinicaltrials.gov) - Jul 11, 2016
P3, N=344, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Active, not recruiting --> Completed No longer recruiting --> Completed
- Epogen (epoetin alfa) / Amgen, Aranesp (darbepoetin alfa) / Amgen, Kyowa Kirin
New P4 trial, Reimbursement, HEOR: Cost Comparison Study of Darbepoetin Versus Epoetin Therapy to Treat Anemia in Hemodialysis Patients (clinicaltrials.gov) - Jun 29, 2016
P4, N=50, Completed, Sponsor: Andrea L Woodland
- Epogen (epoetin alfa) / Amgen
Trial initiation date, Trial primary completion date: Erythropoietin to Prevent Unnecessary Transfusions In Patients With Cyanotic CHD - A Prospective Control Trial (clinicaltrials.gov) - Jun 23, 2016
P2, N=40, Not yet recruiting, Sponsor: University of California, San Diego
No longer recruiting --> Completed Initiation date: Sep 2015 --> Sep 2016 | Trial primary completion date: Sep 2017 --> Sep 2018
- || Epogen (epoetin alfa) / Amgen
New P3 trial: High-dose Erythropoietin for Asphyxia and Encephalopathy (clinicaltrials.gov) - Jun 23, 2016
P3, N=500, Not yet recruiting, Sponsor: University of California, San Francisco
- | Epogen (epoetin alfa) / Amgen
New P1/2 trial, Surgery: EPOgen and Restrictive Transfusions in Patients Undergoing Cardiac Surgery (EPORT) (clinicaltrials.gov) - Jun 16, 2016
P1/2, N=200, Recruiting, Sponsor: Johns Hopkins University
- |||| Epogen (epoetin alfa) / Amgen
Trial completion: Evaluation of Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis (clinicaltrials.gov) - Jun 1, 2016
P4, N=217, Completed, Sponsor: Amgen
Initiation date: Sep 2015 --> Sep 2016 | Trial primary completion date: Sep 2017 --> Sep 2018 Active, not recruiting --> Completed
- ||||||| Mircera (methoxy polyethylene glycol-epoetin beta) / Roche, CSL Behring
Trial completion: A Study of Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients. (clinicaltrials.gov) - May 23, 2016
P3, N=572, Completed, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed No longer recruiting --> Completed
- | Epogen (epoetin alfa) / Amgen
Enrollment closed, Combination therapy: NCI-2009-01173: Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia (clinicaltrials.gov) - May 19, 2016
P3, N=252, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
No longer recruiting --> Completed Recruiting --> Active, not recruiting
- ||||| Evrenzo (roxadustat) / Astellas, AstraZeneca, FibroGen
Enrollment change: Himalayas: Safety and Efficacy Study of Roxadustat (FG-4592) for the Treatment of Anemia in End-Stage Renal Disease (ESRD) Newly Initiated Dialysis Participants (clinicaltrials.gov) - Apr 25, 2016
P3, N=750, Recruiting, Sponsor: FibroGen
Recruiting --> Active, not recruiting N=1000 --> 750
- | Epoyet (epoetin alfa biosimilar) / Procaps, Biogalenic, Delta Farma, Biosidus, Pentafarma
Trial completion, Trial primary completion date: Epoetin Alfa (Hemax (clinicaltrials.gov) - Apr 7, 2016
P4, N=30, Completed, Sponsor: Bio Sidus SA
N=1000 --> 750 Recruiting --> Completed | Trial primary completion date: Jun 2013 --> Nov 2014
- Epogen (epoetin alfa) / Amgen
Enrollment change, Trial withdrawal: Erythropoietin Alfa in Elderly Subjects With Unexplained Anemia (clinicaltrials.gov) - Mar 24, 2016
P=N/A, N=0, Withdrawn, Sponsor: Stanford University
Recruiting --> Completed | Trial primary completion date: Jun 2013 --> Nov 2014 N=20 --> 0 | Recruiting --> Withdrawn
- ||||||| Epogen (epoetin alfa) / Amgen
Trial completion: Research Into the Treatment of Anemia for Critically Ill Patients Admitted to Intensive Care Units (ICU) (clinicaltrials.gov) - Feb 27, 2016
P3, N=1460, Completed, Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
N=20 --> 0 | Recruiting --> Withdrawn No longer recruiting --> Completed
- ||||||| Mircera (methoxy polyethylene glycol-epoetin beta) / Roche, CSL Behring
Trial completion: A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients (clinicaltrials.gov) - Feb 27, 2016
P3, N=673, Completed, Sponsor: Hoffmann-La Roche
No longer recruiting --> Completed No longer recruiting --> Completed
- ||||||| Epogen (epoetin alfa) / Amgen
Trial completion, Surgery: Study of the Efficacy and Safety of Epoetin Alfa Administered Weekly in Patients With Gastric or Rectal Cancers Undergoing a Treatment Plan of Preoperative Chemotherapy and Radiation Therapy, Followed by Surgery (clinicaltrials.gov) - Feb 27, 2016
P3, N=60, Completed, Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
No longer recruiting --> Completed Active, not recruiting --> Completed
- ||||| Mircera (methoxy polyethylene glycol-epoetin beta) / Roche, CSL Behring
Enrollment change, Trial primary completion date: A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients. (clinicaltrials.gov) - Feb 16, 2016
P3, N=424, Completed, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed N=661 --> 424 | Trial primary completion date: Apr 2009 --> Oct 2008
- ||||||| Epogen (epoetin alfa) / Amgen
Trial completion, Trial primary completion date: An Efficacy Study for Epoetin Alfa in Anemic Patients With Myelodysplastic Syndromes (clinicaltrials.gov) - Feb 4, 2016
P3, N=131, Completed, Sponsor: Janssen-Cilag International NV
N=661 --> 424 | Trial primary completion date: Apr 2009 --> Oct 2008 Active, not recruiting --> Completed | Trial primary completion date: Dec 2015 --> Jan 2015
- |||| Musredo (molidustat) / Bayer
Trial completion: DIALOGUE4: Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934 (clinicaltrials.gov) - Jan 15, 2016
P2, N=201, Completed, Sponsor: Bayer
Active, not recruiting --> Completed | Trial primary completion date: Dec 2015 --> Jan 2015 Active, not recruiting --> Completed
- |||||||||| Evrenzo (roxadustat) / Astellas, AstraZeneca, FibroGen
New P3 trial: FG-4592 for Treatment of Anemia in Subjects With Chronic Kidney Disease (clinicaltrials.gov) - Jan 15, 2016
P3, N=300, Recruiting, Sponsor: FibroGen
- | Epogen (epoetin alfa) / Amgen
New P4 trial: Pure Red Cell Aplasia in Patients With Chronic Kidney Disease and in Use of Epoetin Alfa (clinicaltrials.gov) - Jan 6, 2016
P4, N=531, Enrolling by invitation, Sponsor: The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)
- Epogen (epoetin alfa) / Amgen
Enrollment change, Trial withdrawal: Effect of Recombinant Erythropoietin on Numbers of Circulating Endothelial Progenitor Cells in Subacute TBI (clinicaltrials.gov) - Jan 4, 2016
P2, N=0, Withdrawn, Sponsor: Uniformed Services University of the Health Sciences
Active, not recruiting --> Completed N=30 --> 0 | Not yet recruiting --> Withdrawn
- ||||| Epogen (epoetin alfa) / Amgen
Enrollment closed, Trial primary completion date, Metastases: A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy (clinicaltrials.gov) - Nov 24, 2015
P3, N=2100, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
N=30 --> 0 | Not yet recruiting --> Withdrawn Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2017 --> Jul 2014